Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.25
AKRX's Cash-to-Debt is ranked lower than
82% of the 719 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. AKRX: 0.25 )
Ranked among companies with meaningful Cash-to-Debt only.
AKRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.26 Max: N/A
Current: 0.25
Equity-to-Asset 0.42
AKRX's Equity-to-Asset is ranked lower than
75% of the 660 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. AKRX: 0.42 )
Ranked among companies with meaningful Equity-to-Asset only.
AKRX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.18  Med: 0.52 Max: 0.86
Current: 0.42
0.18
0.86
Interest Coverage 7.67
AKRX's Interest Coverage is ranked lower than
77% of the 641 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 101.29 vs. AKRX: 7.67 )
Ranked among companies with meaningful Interest Coverage only.
AKRX' s Interest Coverage Range Over the Past 10 Years
Min: 1.71  Med: 7.4 Max: No Debt
Current: 7.67
Piotroski F-Score: 6
Altman Z-Score: 3.10
Beneish M-Score: -1.64
WACC vs ROIC
12.67%
15.86%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 29.33
AKRX's Operating Margin % is ranked higher than
93% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.86 vs. AKRX: 29.33 )
Ranked among companies with meaningful Operating Margin % only.
AKRX' s Operating Margin % Range Over the Past 10 Years
Min: -37.46  Med: 17.96 Max: 29.91
Current: 29.33
-37.46
29.91
Net Margin % 16.50
AKRX's Net Margin % is ranked higher than
83% of the 673 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. AKRX: 16.50 )
Ranked among companies with meaningful Net Margin % only.
AKRX' s Net Margin % Range Over the Past 10 Years
Min: -36.24  Med: 14.56 Max: 31.41
Current: 16.5
-36.24
31.41
ROE % 24.93
AKRX's ROE % is ranked higher than
87% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.66 vs. AKRX: 24.93 )
Ranked among companies with meaningful ROE % only.
AKRX' s ROE % Range Over the Past 10 Years
Min: -50.57  Med: 21.2 Max: 35.12
Current: 24.93
-50.57
35.12
ROA % 9.45
AKRX's ROA % is ranked higher than
77% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.48 vs. AKRX: 9.45 )
Ranked among companies with meaningful ROA % only.
AKRX' s ROA % Range Over the Past 10 Years
Min: -33.5  Med: 8.42 Max: 24.27
Current: 9.45
-33.5
24.27
ROC (Joel Greenblatt) % 69.84
AKRX's ROC (Joel Greenblatt) % is ranked higher than
90% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.44 vs. AKRX: 69.84 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AKRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -48.35  Med: 56.63 Max: 77.64
Current: 69.84
-48.35
77.64
3-Year Revenue Growth Rate 47.10
AKRX's 3-Year Revenue Growth Rate is ranked higher than
95% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. AKRX: 47.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AKRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -37.1  Med: 4.3 Max: 56.6
Current: 47.1
-37.1
56.6
3-Year EBITDA Growth Rate 54.10
AKRX's 3-Year EBITDA Growth Rate is ranked higher than
89% of the 574 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.70 vs. AKRX: 54.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AKRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -64.1  Med: 45.6 Max: 149.9
Current: 54.1
-64.1
149.9
3-Year EPS without NRI Growth Rate 47.30
AKRX's 3-Year EPS without NRI Growth Rate is ranked higher than
89% of the 541 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. AKRX: 47.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AKRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -50.4  Med: 27.9 Max: 68.3
Current: 47.3
-50.4
68.3
» AKRX's 10-Y Financials

Financials (Next Earnings Date: 2017-06-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

AKRX Guru Trades in Q1 2016

John Paulson 9,318,600 sh (+223.66%)
Murray Stahl 27,192 sh (+64.32%)
Mario Gabelli 46,300 sh (+48.87%)
Andreas Halvorsen 2,081,398 sh (+13.04%)
George Soros Sold Out
Steven Cohen Sold Out
Columbia Wanger 2,096,707 sh (-23.36%)
» More
Q2 2016

AKRX Guru Trades in Q2 2016

Jim Simons 175,600 sh (New)
Joel Greenblatt 403,835 sh (New)
Steven Cohen 120,600 sh (New)
Paul Tudor Jones 30,765 sh (New)
George Soros 38,400 sh (New)
Andreas Halvorsen Sold Out
Columbia Wanger 2,076,628 sh (-0.96%)
John Paulson 9,012,900 sh (-3.28%)
Mario Gabelli 44,600 sh (-3.67%)
Murray Stahl 15,028 sh (-44.73%)
» More
Q3 2016

AKRX Guru Trades in Q3 2016

Richard Snow 149,070 sh (New)
Lee Ainslie 116,040 sh (New)
Paul Tudor Jones 31,282 sh (+1.68%)
Mario Gabelli 44,600 sh (unchged)
George Soros Sold Out
Jim Simons Sold Out
Steven Cohen Sold Out
John Paulson 8,974,400 sh (-0.43%)
Murray Stahl 14,766 sh (-1.74%)
Joel Greenblatt 227,948 sh (-43.55%)
Columbia Wanger 1,064,814 sh (-48.72%)
» More
Q4 2016

AKRX Guru Trades in Q4 2016

First Pacific Advisors 136,990 sh (New)
Steven Cohen 315,200 sh (New)
David Dreman 18,498 sh (New)
Richard Snow 376,150 sh (+152.33%)
Murray Stahl 19,927 sh (+34.95%)
Lee Ainslie 151,370 sh (+30.45%)
Mario Gabelli 56,900 sh (+27.58%)
Paul Tudor Jones 37,381 sh (+19.50%)
Columbia Wanger 1,179,455 sh (+10.77%)
John Paulson 8,686,500 sh (-3.21%)
Joel Greenblatt 145,407 sh (-36.21%)
» More
» Details

Insider Trades

Latest Guru Trades with AKRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:OTCPK:IZQVF, NAS:IRWD, NAS:HZNP, NAS:ENDP, NYSE:CTLT, OTCPK:STDAF, NAS:MDCO, NAS:NBIX, NAS:PCRX, NYSE:PTHN, NAS:RDUS, NAS:SUPN, NAS:OPK, NAS:EGRX, OTCPK:EVTCY, NYSE:MNK, OTCPK:KHTRF, NAS:SGYP, OTCPK:CSWYF, NYSE:DPLO » details
Traded in other countries:FDA.Germany,
Akorn Inc manufactures and markets a full line of diagnostic and therapeutic ophthalmic pharmaceuticals as well as niche hospital drugs and injectable pharmaceuticals.

Akorn manufactures ophthalmology and dermatology products as well as injectables. In ophthalmology, the firm primarily sells generic and over-the-counter products but has a small branded portfolio that was purchased from Merck. The firm is primarily focused on the United States.

Ratios

vs
industry
vs
history
PE Ratio 15.37
AKRX's PE Ratio is ranked higher than
79% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.50 vs. AKRX: 15.37 )
Ranked among companies with meaningful PE Ratio only.
AKRX' s PE Ratio Range Over the Past 10 Years
Min: 12.14  Med: 34.14 Max: 495
Current: 15.37
12.14
495
Forward PE Ratio 14.35
AKRX's Forward PE Ratio is ranked higher than
58% of the 89 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.46 vs. AKRX: 14.35 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 15.37
AKRX's PE Ratio without NRI is ranked higher than
78% of the 581 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.49 vs. AKRX: 15.37 )
Ranked among companies with meaningful PE Ratio without NRI only.
AKRX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.14  Med: 34.14 Max: 495
Current: 15.37
12.14
495
Price-to-Owner-Earnings 39.57
AKRX's Price-to-Owner-Earnings is ranked lower than
59% of the 296 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.92 vs. AKRX: 39.57 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
AKRX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 11.08  Med: 52.34 Max: 273.15
Current: 39.57
11.08
273.15
PB Ratio 3.45
AKRX's PB Ratio is ranked lower than
56% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.93 vs. AKRX: 3.45 )
Ranked among companies with meaningful PB Ratio only.
AKRX' s PB Ratio Range Over the Past 10 Years
Min: 1.42  Med: 6.41 Max: 16.87
Current: 3.45
1.42
16.87
PS Ratio 2.57
AKRX's PS Ratio is ranked higher than
55% of the 727 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.85 vs. AKRX: 2.57 )
Ranked among companies with meaningful PS Ratio only.
AKRX' s PS Ratio Range Over the Past 10 Years
Min: 0.75  Med: 6.11 Max: 12.93
Current: 2.57
0.75
12.93
Price-to-Free-Cash-Flow 32.22
AKRX's Price-to-Free-Cash-Flow is ranked lower than
60% of the 228 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 24.42 vs. AKRX: 32.22 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
AKRX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.51  Med: 82.79 Max: 2950
Current: 32.22
10.51
2950
Price-to-Operating-Cash-Flow 17.09
AKRX's Price-to-Operating-Cash-Flow is ranked higher than
50% of the 290 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.18 vs. AKRX: 17.09 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AKRX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.08  Med: 44.77 Max: 189.57
Current: 17.09
9.08
189.57
EV-to-EBIT 10.50
AKRX's EV-to-EBIT is ranked higher than
82% of the 545 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.11 vs. AKRX: 10.50 )
Ranked among companies with meaningful EV-to-EBIT only.
AKRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -4983.2  Med: 13.8 Max: 213.1
Current: 10.5
-4983.2
213.1
EV-to-EBITDA 8.28
AKRX's EV-to-EBITDA is ranked higher than
84% of the 573 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.30 vs. AKRX: 8.28 )
Ranked among companies with meaningful EV-to-EBITDA only.
AKRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -498.5  Med: 16.35 Max: 2955.7
Current: 8.28
-498.5
2955.7
PEG Ratio 0.31
AKRX's PEG Ratio is ranked higher than
93% of the 283 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.79 vs. AKRX: 0.31 )
Ranked among companies with meaningful PEG Ratio only.
AKRX' s PEG Ratio Range Over the Past 10 Years
Min: 0.06  Med: 0.39 Max: 0.66
Current: 0.31
0.06
0.66
Shiller PE Ratio 61.92
AKRX's Shiller PE Ratio is ranked lower than
62% of the 159 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.64 vs. AKRX: 61.92 )
Ranked among companies with meaningful Shiller PE Ratio only.
AKRX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 50.27  Med: 136.9 Max: 2690.5
Current: 61.92
50.27
2690.5
Current Ratio 3.91
AKRX's Current Ratio is ranked higher than
70% of the 614 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. AKRX: 3.91 )
Ranked among companies with meaningful Current Ratio only.
AKRX' s Current Ratio Range Over the Past 10 Years
Min: 0.3  Med: 2.28 Max: 5.51
Current: 3.91
0.3
5.51
Quick Ratio 2.91
AKRX's Quick Ratio is ranked higher than
70% of the 613 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.73 vs. AKRX: 2.91 )
Ranked among companies with meaningful Quick Ratio only.
AKRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.06  Med: 1.12 Max: 4.26
Current: 2.91
0.06
4.26
Days Inventory 151.52
AKRX's Days Inventory is ranked lower than
68% of the 626 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 115.23 vs. AKRX: 151.52 )
Ranked among companies with meaningful Days Inventory only.
AKRX' s Days Inventory Range Over the Past 10 Years
Min: 118.8  Med: 148.93 Max: 188.37
Current: 151.52
118.8
188.37
Days Sales Outstanding 92.54
AKRX's Days Sales Outstanding is ranked lower than
61% of the 571 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.23 vs. AKRX: 92.54 )
Ranked among companies with meaningful Days Sales Outstanding only.
AKRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 25.46  Med: 61.64 Max: 123.33
Current: 92.54
25.46
123.33
Days Payable 49.10
AKRX's Days Payable is ranked lower than
70% of the 522 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 73.13 vs. AKRX: 49.10 )
Ranked among companies with meaningful Days Payable only.
AKRX' s Days Payable Range Over the Past 10 Years
Min: 19.92  Med: 53.34 Max: 123.76
Current: 49.1
19.92
123.76

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.80
AKRX's 3-Year Average Share Buyback Ratio is ranked lower than
66% of the 441 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.00 vs. AKRX: -8.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AKRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -63.1  Med: -4.3 Max: -0.9
Current: -8.8
-63.1
-0.9

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 1.70
AKRX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
66% of the 314 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.37 vs. AKRX: 1.70 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AKRX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.63  Med: 10.6 Max: 40.47
Current: 1.7
1.63
40.47
Price-to-Median-PS-Value 0.42
AKRX's Price-to-Median-PS-Value is ranked higher than
94% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.20 vs. AKRX: 0.42 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AKRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.08  Med: 0.38 Max: 1.98
Current: 0.42
0.08
1.98
Price-to-Peter-Lynch-Fair-Value 0.61
AKRX's Price-to-Peter-Lynch-Fair-Value is ranked higher than
87% of the 173 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.61 vs. AKRX: 0.61 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
AKRX' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.54  Med: 0.9 Max: 1.77
Current: 0.61
0.54
1.77
Earnings Yield (Greenblatt) % 9.52
AKRX's Earnings Yield (Greenblatt) % is ranked higher than
89% of the 788 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. AKRX: 9.52 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AKRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.5  Med: 4.1 Max: 11.1
Current: 9.52
0.5
11.1
Forward Rate of Return (Yacktman) % 56.69
AKRX's Forward Rate of Return (Yacktman) % is ranked higher than
95% of the 364 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.76 vs. AKRX: 56.69 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
AKRX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -15.5  Med: -0.9 Max: 1017.9
Current: 56.69
-15.5
1017.9

More Statistics

Revenue (TTM) (Mil) $1,117
EPS (TTM) $ 1.48
Beta1.79
Short Percentage of Float12.64%
52-Week Range $17.61 - 35.40
Shares Outstanding (Mil)124.45

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1,032 1,073 1,125
EPS ($) 1.60 1.73 1.80
EPS without NRI ($) 1.60 1.73 1.80
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for AKRX

Headlines

Articles On GuruFocus.com
Valeant: It's Not a Game of Chess Part I Mar 16 2017 
John Paulson's Bargain Stock Jan 30 2017 
Casualty List Has Done Well; Here’s the Latest Jan 18 2017 
Teva: Good Value, Questionable Management? Jan 02 2017 
Integer Investments: Akorn Has 100% Upside Potential Jan 01 2017 
Siegfried Holdings, Held by Tweedy Browne, Way Undervalued Jul 22 2016 
John Paulson Bulks Up Health Care Bet Feb 17 2016 
Analysts Disagree Over Significance of Akorn, Inc’s Financial Errors Apr 28 2015 
Weekly CEO Sells Highlight: Akorn Inc, Under Armour Inc, Anadarko Petroleum Corp, and Graphic Packag Aug 09 2014 
WEEKLY CFO SELLS HIGHLIGHT: AKRX, FIO, OVRL, VRTX Oct 21 2012 

More From Other Websites
Is The Market Expensive? Buffett Says No Mar 20 2017
Blog Coverage Mylan Announces Launch of Generic Version of Pfizer's Antidepressant PRISTIQ in US Mar 13 2017
AKORN INC Financials Mar 07 2017
ETFs with exposure to Akorn, Inc. : March 6, 2017 Mar 06 2017
Does Reward Potential Still Outweigh The Risk In Akorn Shares? Mar 06 2017
Bullish and Bearish Reversals in the Market Mar 06 2017
Red-Hot Biotech Companies Highlight Jefferies Top Stocks to Buy Mar 06 2017
New Strong Sell Stocks for March 6th Mar 06 2017
Perrigo Joins Firms With Generic Drugs Under U.S. Glare Mar 03 2017
Akorn, Inc. :AKRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 2, 2017 Mar 02 2017
AKORN INC Files SEC form 8-K, Regulation FD Disclosure Mar 02 2017
Akorn Receives FDA Approval for Ephedrine Sulfate Injection, USP Mar 02 2017
7 Stocks Trending With Monster Volume Mar 02 2017
Akorn Inc Earnings Call scheduled for 10:00 am ET today Mar 01 2017
Akorn meets 4Q profit forecasts Mar 01 2017
Akorn meets 4Q profit forecasts Mar 01 2017
AKORN INC Files SEC form 8-K, Results of Operations and Financial Condition Mar 01 2017
Q4 2016 Akorn Inc Earnings Release - Before Market Open Mar 01 2017
Akorn Provides Fourth Quarter and Full Year 2016 Results and Outlines Full Year 2017 Guidance Mar 01 2017
Akorn Receives Approval for Mycophenolate Mofetil for Injection, USP Feb 28 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)